Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Predictor Did Not Stratify NSCLC Patients for VTE Risk
J Thromb Haemost; ePub 2016 Sep 9; Mansfield, et al
The Khorana Risk Score (KRS) did not adequately categorize people with lung cancer who were at the highest risk of venous thromboembolism (VTE) in a study involving more than 700 individuals.
Investigators used a prospectively collected lung cancer database to validate how well KRS predicted VTE. Participants were predominantly male. All had non small-cell lung cancer, and 40% had metastatic disease. Among the results:
• Median follow-up was ~15 months.
• ~1 in every 10 patients had VTE.
• ~8 in every 10 died.
• High KRS was not linked with VTE when compared with an intermediate score.
• Those with high KRS had a 70% higher mortality risk.
The authors noted that a better risk stratification approach is needed prior to implementing a primary prevention strategy.
Mansfield A, Tafur A, Wang C, Kourelis T, Wysokinska E, Yang P. Predictors of active cancer thromboembolic outcomes: Validation of the Khorana score among patients with lung cancer. [Published online ahead of print September 9, 2016]. J Thromb Haemost. doi:10.1111/jth.13378.